Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

Guggenheim downgraded Novo Nordisk (NVO) to Neutral from Buy.Stay Ahead of the Market: Discover outperforming stocks and invest smarter with ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Novo Nordisk has promoted Rishang Deoras to Global Director - Diabetes Commercial Unit.Deoras shared the news in a LinkedIn ...

Novo Nordisk ) is going big in Brazil. The drugmaker behind Ozempic and Wegovy just dropped a $1.09 billion investment to ...

Novo Nordisk, the Danish pharmaceutical giant behind obesity drug, Wegovy, has engaged Slingshot to develop and manage its ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...